Proven Precision for Neonatal Care
IMT Innovations Expands the Commercial Reach of its box Ventilator Platform with Successful Neonatal Validation
IMT Innovations today announced the successful validation of its box ventilator technology for neonatal applications, demonstrating the platform's ability to accurately deliver the ultra-low tidal volumes and precise pressure control required for the most demanding patients.
The achievement significantly expands the commercial scope of the box platform and confirms its applicability across multiple respiratory care segments.
Neonatal ventilation represents one of the highest technical and regulatory barriers within the global ventilator market. By successfully addressing this segment, IMT's box platform now supports dedicated neonatal and pediatric applications while maintaining a broader platform architecture that can be configured for additional respiratory care markets.
"This milestone further validates our strategy of building a scalable ventilator platform rather than a single-purpose device," said Harri Friberg, CEO of IMT Innovations. "The ability to serve neonatal patients demonstrates the precision and robustness of the underlying technology and significantly increases the number of commercial opportunities available to future licensing partners."
With neonatal validation now complete, IMT is actively making available four dedicated licensing segments for qualified US partners:
- Hospital Licence (ICU/NIV)
Acute hospital critical care, invasive ventilation, and non-invasive NIV, including the growing demand created by the Philips V60 discontinuation
- Advanced Homecare Licence
Long-term ventilatory support for chronic respiratory disease patients at home, including COPD, neuromuscular disease, and post-ICU transition care.
- Emergency Transport Licence
Pre-hospital, air medical, and ground transport applications, supported by the platform's eight-hour hot-swap battery and dual oxygen source compatibility.
- Neonatal Licence (Global Licence is Exclusively committed)
Dedicated NICU and pediatric intensive care applications, now validated to the ultra-low tidal volume and precision pressure requirements of neonatal patients.
Each segment is available as a separate territorial exclusive licence in the United States. Partners may acquire a single segment or a combination, depending on their existing commercial infrastructure and market focus.
Unlike conventional ventilator programs that require substantial development resources and lengthy timelines, the box platform is designed to be deployed through regional licensing partnerships. Licensees gain access to a complete technology package, including manufacturing know-how, supply-chain architecture, technical documentation and regulatory support, enabling the establishment of independent ventilator businesses with reduced development risk and accelerated market entry.
The successful neonatal validation further strengthens the attractiveness of the platform for strategic partners seeking access to high-value respiratory care markets without the need to develop a ventilator platform from the ground up.
As healthcare systems worldwide continue to seek resilient and locally controlled critical-care infrastructure, IMT believes its platform-based licensing model is uniquely positioned to support the next generation of ventilator deployment and commercialization.
We invite qualified manufacturers, distributors, and investors interested in any of the four US license segments to click the link below to request access to our licensing documentation or to contact our commercial team directly via our "contact" page.
